Söndag 27 April | 03:49:17 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-22 07:50 Kvartalsrapport 2025-Q3
2025-07-18 07:50 Kvartalsrapport 2025-Q2
2025-04-30 N/A X-dag ordinarie utdelning VIMIAN 0.00 SEK
2025-04-29 N/A Årsstämma
2025-04-29 07:50 Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2022-08-24 07:45:00

Solid performance in challenging macroeconomic environment

  • Revenue increased by 70 per cent to EUR 67m (39.4), of which 1.0 per cent was organic growth (5.2 per cent excluding livestock diagnostics)
  • Adjusted EBITA EUR 17.7m (12.2), corresponding to an adjusted EBITA margin of 26.4 per cent (30.8)
  • Operating profit totalled EUR 7.9m (1.6), including items affecting comparability of EUR -5.7m (-7.6). Profit for the quarter totalled EUR 10.0m (-3.0)
  • Earnings per share before dilution EUR 0.03 (-0.01) and after dilution EUR 0.03 (-0.01)

“Vimian delivers another solid quarter with 70 per cent revenue growth to EUR 67 million, and an adjusted EBITA margin of 26.4 per cent. Excluding livestock diagnostics, a market that continues to face headwinds, organic growth was 5.2 per cent and 10.3 per cent on a pro-forma basis. The Group shows resilience and solidifies market positions in a historically challenging macroeconomic environment. We are well positioned with a focus on advanced care and chronic diseases, targeting an ageing pet population”, says Dr. Fredrik Ullman, CEO of Vimian Group.

Last twelve months pro-forma revenues (including the full year impact of all acquisitions completed during the twelve months ending 30 June) reached EUR 269.8 million and pro-forma EBITDA EUR 79.6 million.

“Over the past one and half year, we have doubled the size of the company and significantly strengthened our position in the global animal health market, entering new geographies, adding new portfolios and technologies, and advancing our innovation pipeline. In the second quarter alone, we completed four strategic add-on acquisitions taking pro-forma revenues to EUR 269.8 million”, says Dr. Fredrik Ullman, CEO of Vimian Group.

A telephone and web conference will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
SE: +46850516386
UK: +442031984884
US: +14123176300
Pin code: 6962788#

To attend the webcast:
Link: https://tv.streamfabriken.com/vimian-group-q2-2022

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.